Home siRNA SR313060
FIP1L1 (ID 81608) Trilencer-27 Human siRNA
- FIP1L1 (Human) - 3 unique 27mer siRNA duplexes - 2 nmol each (Locus ID 81608)
- Included - SR30004, Trilencer-27 Universal Scrambled Negative Control siRNA Duplex - 2 nmol
- Included - SR30005, RNAse free siRNA Duplex Resuspension Buffer - 2 ml
- SiTran1.0: Transfection reagent designed for RNAi duplex (0.5 ml)
* These siRNA duplexes were designed to be effective against all transcriptional variants at this gene locus.
** Delivery time is an estimate in business days. Occasional delays may occur due to unforeseen complexities in the preparation of your construct. International customers may expect an additional 1-2 weeks in shipping.
Also for FIP1L1 (Locus ID 81608)
|Amount: 2 nmol each, lyophilized||Purity: HPLC purified|
|Quality Control: Tested by ESI-MS||Sequences: Available with shipment|
|Stability: One year from date of shipment when stored at -20ºC||Shipment: Ambient|
|# of transfections: Approximately 330 transfections/2nmol in 24-well plate under optimized conditions (final conc. 10 nM)|
|Note: Single siRNA duplex (10nmol) can be ordered. See details at http://www.origene.com/siRNA/|
|Synonyms: Rhe;DKFZp586K0717; FLJ33619; FIP1 like 1; rearranged in hypereosinophilia; FIP1 like 1 (S. cerevisiae)|
|Summary: This gene encodes a subunit of the CPSF (cleavage and polyadenylation specificity factor) complex that polyadenylates the 3' end of mRNA precursors. This gene, the homolog of yeast Fip1 (factor interacting with PAP), binds to U-rich sequences of pre-mRNA and stimulates poly(A) polymerase activity. Its N-terminus contains a PAP-binding site and its C-terminus an RNA-binding domain. An interstitial chromosomal deletion on 4q12 creates an in-frame fusion of human genes FIP1L1 and PDGFRA (platelet-derived growth factor receptor, alpha). The FIP1L1-PDGFRA fusion gene encodes a constitutively activated tyrosine kinase that joins the first 233 amino acids of FIP1L1 to the last 523 amino acids of PDGFRA. This gene fusion and chromosomal deletion is the cause of some forms of idiopathic hypereosinophilic syndrome (HES). This syndrome, recently reclassified as chronic eosinophilic leukemia (CEL), is responsive to treatment with tyrosine kinase inhibitors. Alternative splicing results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, Oct 2008].|Performance Guranteed:
OriGene guarantees that at least two of the three Dicer-Substrate duplexes in the kit will provide at least 70% or more knockdown of the target mRNA when used at 10 nM concentration by quantitative RT-PCR when the TYE-563 fluorescent transfection control duplex (cat# SR30002) indicates that >90% of the cells have been transfected and the HPRT positive control (cat# SR30003) provides 90% knockdown efficiency.
For non-conforming siRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the siRNA kit. To arrange for a free replacement with newly designed duplexes, please contact Technical Services at firstname.lastname@example.org. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled siRNA control (quantitative RT-PCR data required).